

Adjunctive Doxycycline for Central Nervous System Tuberculosis

NCT06446245

Status	RECRUITING
Phase	Phase 2
Sponsor	National University Hospital, Singapore
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (9)

- Aged 21 years and above.
- Patients receiving d 7 days of TB treatment or about to start combination TB treatment, including injectable agents, where required.
- Patients with clinical evidence of TB meningitis, as per established diagnostic criteria, defined as either definite, probable or possible CNS-TB:
 - "Definite" CNS-TB would be defined if acid-fast bacilli (AFB) or a positive nucleic acid amplification test for *M. tuberculosis* in the cerebrospinal fluid of patients.
 - "Probable" CNS-TB would be defined if the patient exhibit one or more of the following: suspected pulmonary tuberculosis on chest radiography, acid-fast bacilli found in any specimen other than the cerebrospinal fluid or clinical evidence of other extrapulmonary tuberculosis.

... and 4 more (see full listing online)

Exclusion (9)

- Active Cancer
- Pregnant or breastfeeding
- Allergies to tetracyclines
- Patients on retinoic acid, neuromuscular blocking agents or pimozide which may increase the risk of drug toxicity.
- Autoimmune disease and/or on systemic immunosuppressants.

... and 4 more (see full listing online)

Locations (5 total)

Adam Malik Hospital, Medan, Indonesia
Universitas Sumatera Utara, Medan, Indonesia
Sarawak General Hospital, Kuching, Sarawak, Malaysia
... and 2 more locations

<https://clinicaltrials.gov/study/NCT06446245>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).